164.19
前日終値:
$158.55
開ける:
$158.31
24時間の取引高:
835.01K
Relative Volume:
1.03
時価総額:
$9.68B
収益:
$551.35M
当期純損益:
$-189.33M
株価収益率:
-49.88
EPS:
-3.2916
ネットキャッシュフロー:
$-35.09M
1週間 パフォーマンス:
+6.97%
1か月 パフォーマンス:
-8.56%
6か月 パフォーマンス:
+52.51%
1年 パフォーマンス:
+101.34%
Glaukos Corp Stock (GKOS) Company Profile
Compare GKOS vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GKOS
Glaukos Corp
|
164.19 | 9.11B | 551.35M | -189.33M | -35.09M | -3.2916 |
|
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-10-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Buy |
| 2025-05-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-12-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 開始されました | Truist | Buy |
| 2023-11-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-14 | 再開されました | Stephens | Overweight |
| 2022-10-04 | 開始されました | Needham | Buy |
| 2022-07-12 | アップグレード | Stifel | Hold → Buy |
| 2022-02-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | アップグレード | BTIG Research | Neutral → Buy |
| 2021-11-03 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | アップグレード | Citigroup | Sell → Neutral |
| 2020-12-09 | 開始されました | Oppenheimer | Perform |
| 2020-11-17 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 開始されました | Jefferies | Hold |
| 2020-03-05 | 開始されました | Citigroup | Sell |
| 2020-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-01-06 | アップグレード | Berenberg | Hold → Buy |
| 2019-12-12 | ダウングレード | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 開始されました | BTIG Research | Neutral |
| 2018-08-30 | 開始されました | Berenberg | Hold |
| 2018-08-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 繰り返されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-04-13 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-01 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-03-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-01-06 | アップグレード | Stifel | Hold → Buy |
| 2016-10-27 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Glaukos Corp (GKOS) 最新ニュース
Form 144 GLAUKOS Corp For: 26 September By Investing.com - Investing.com Nigeria
A Glaukos (NYSE: GKOS) officer proposes selling 1,615 shares on September 25. - Stock Titan
Presbyopia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | AbbVie, Orasis Pharma, Eyenovia, Glaukos Corp., Ocuphire Pharma, Novartis - Barchart.com
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now - Yahoo Finance
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could - The National Law Review
Zacks Investment Research - globes.co.il
A Look at Glaukos Corp (GKOS) After 4.0% Decline -- GF Value $15 - gurufocus.com
Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $210 - moomoo.com
$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today - Benzinga
Stephen Curry is sharing his story to help families spot signs of a sight-threatening eye disease. - stocktitan.net
Glaukos (GKOS), Why Is It Back In The Spotlight? - Yahoo Finance
Glaukos Corporation (GKOS) Options ChainYahoo Finance - Yahoo! Finance Canada
GKOS Maintained by Jefferies -- Price Target Raised to $210 - GuruFocus
Glaukos stock gains institutional support as Bank of America builds position - AD HOC NEWS
Glaukos chief development officer Tomas Navratil sells $243k in shares - Investing.com
Glaukos Corp (GKOS) Stock Down 4.8% but Still Overvalued -- GF S - GuruFocus
Glaukos (NYSE: GKOS) officer lines up new stock sale after $2.48M August trade - Stock Titan
Glaukos Corp (GKOS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cyclo3pss Corporation (CYPS) Peer Comparison – Compare with Others - Value Research
Glaukos Corp (GKOS) Shares Fall 5.2% -- What GF Score of 77 Tells Investors - GuruFocus
Why Glaukos Shares Are Trading Lower Today - Quiver Quantitative
If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Glaukos at Wells Fargo conference: launch ramps, reimbursement risks - Investing.com
Glaukos at Wells Fargo conference: launch ramps, reimbursement risks By Investing.com - Investing.com Canada
Is Glaukos Corp (GKOS) Overvalued After 4.3% Rally? GF Value Say - GuruFocus
Glaukos Corp (NYSE: GKOS) Share Price, GKOS Stock News, GKOS Share Price & Updates - Kalkine
ZimVie Inc. When-Issued (ZIMVV) Peer Comparison – Compare with Others - Value Research
Enterprise value to EBITDA forward of Glaukos Corp – LSX:A14VCK - TradingView
Precipio Inc. (PRPO) Peer Comparison – Compare with Others - Value Research
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Bruker Corporation (BRKR) Peer Comparison – Compare with Others - valueresearchonline.com
Haemonetics Corporation (HAE) Peer Comparison – Compare with Others - Value Research
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - valueresearchonline.com
Quidel Corporation (QDEL) Peer Comparison – Compare with Others - Value Research
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
UFP Technologies Inc. (UFPT) Peer Comparison – Compare with Others - Value Research
Innovative Eyewear Inc (LUCYW) Peer Comparison – Compare with Others - Value Research
Natus Medical Incorporated (NTUS) Peer Comparison – Compare with Others - Value Research
Repro Med Systems Inc. (KRMD) Peer Comparison – Compare with Others - Value Research
TransMedics Group Inc. (TMDX) Peer Comparison – Compare with Others - Value Research
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
GlucoTrack Inc (GCTK) Peer Comparison – Compare with Others - Value Research
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - Value Research
AtriCure Inc. (ATRC) Peer Comparison – Compare with Others - valueresearchonline.com
IsoPlexis Corporation (ISO) Peer Comparison – Compare with Others - Value Research
Bionano Genomics Inc. (BNGO) Peer Comparison – Compare with Others - Value Research
Pulse Biosciences Inc (DE) (PLSE) Peer Comparison – Compare with Others - Value Research
Glaukos chief development officer sells $2.48m in shares By Investing.com - Investing.com Nigeria
Glaukos chief development officer sells $2.48m in shares - Investing.com
Glaukos Corp (GKOS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):